{"id":"bms-936558-nivolumab","safety":{"commonSideEffects":[{"rate":"30–40","effect":"Fatigue"},{"rate":"20–30","effect":"Rash"},{"rate":"15–25","effect":"Diarrhea"},{"rate":"15–25","effect":"Nausea"},{"rate":"15–20","effect":"Decreased appetite"},{"rate":"3–5","effect":"Immune-mediated pneumonitis"},{"rate":"2–5","effect":"Immune-mediated hepatitis"},{"rate":"2–4","effect":"Immune-mediated colitis"},{"rate":"5–10","effect":"Immune-mediated endocrinopathy (thyroiditis, adrenalitis)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nivolumab is a monoclonal antibody that binds to programmed death receptor-1 (PD-1) on T cells, preventing interaction with its ligands (PD-L1 and PD-L2) expressed on tumor cells and immune cells. This blockade releases the 'brakes' on the immune system, restoring T-cell proliferation, activation, and anti-tumor function. By reinvigorating exhausted T cells, nivolumab enables durable anti-tumor immunity.","oneSentence":"Nivolumab blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:43.233Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Advanced non-small cell lung cancer"},{"name":"Renal cell carcinoma"},{"name":"Classical Hodgkin lymphoma"},{"name":"Squamous cell carcinoma of the head and neck"},{"name":"Urothelial carcinoma"},{"name":"Colorectal cancer (microsatellite instability-high or mismatch repair deficient)"}]},"trialDetails":[{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":"AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT03055013","phase":"PHASE3","title":"Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-28","conditions":"Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7","enrollment":819},{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT01896999","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-07","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":146},{"nctId":"NCT03816345","phase":"PHASE1","title":"Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Autoimmune Disease, Crohn Disease, Dermatomyositis","enrollment":300},{"nctId":"NCT05112601","phase":"PHASE2","title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-02","conditions":"Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":81},{"nctId":"NCT04317105","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-17","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":54},{"nctId":"NCT06203600","phase":"PHASE2, PHASE3","title":"Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-24","conditions":"Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":224},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636},{"nctId":"NCT02496208","phase":"PHASE1","title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-07-22","conditions":"Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma","enrollment":152},{"nctId":"NCT05136196","phase":"PHASE2","title":"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-06","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":150},{"nctId":"NCT02834013","phase":"PHASE2","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-30","conditions":"Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma","enrollment":818},{"nctId":"NCT04840589","phase":"PHASE1","title":"Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-02","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma","enrollment":66},{"nctId":"NCT06029270","phase":"PHASE2","title":"Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-15","conditions":"Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":156},{"nctId":"NCT03233711","phase":"PHASE3","title":"Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-05","conditions":"Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma","enrollment":344},{"nctId":"NCT05896839","phase":"PHASE1, PHASE2","title":"Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-24","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":16},{"nctId":"NCT06064097","phase":"PHASE2","title":"A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-25","conditions":"Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT04145115","phase":"PHASE2","title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-24","conditions":"Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype","enrollment":37},{"nctId":"NCT03816358","phase":"PHASE1","title":"Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-09","conditions":"Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":74},{"nctId":"NCT05308446","phase":"PHASE2","title":"Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-19","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8","enrollment":84},{"nctId":"NCT02978625","phase":"PHASE2","title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-09-27","conditions":"Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma","enrollment":68},{"nctId":"NCT04444921","phase":"PHASE3","title":"EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-11-17","conditions":"Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Metastatic Anal Squamous Cell Carcinoma","enrollment":205},{"nctId":"NCT03502733","phase":"PHASE1","title":"Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-08-14","conditions":"Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":64},{"nctId":"NCT02595944","phase":"PHASE3","title":"Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-22","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7","enrollment":903},{"nctId":"NCT03793166","phase":"PHASE3","title":"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-07","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes","enrollment":1175},{"nctId":"NCT05904080","phase":"PHASE2","title":"Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-19","conditions":"Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT05272384","phase":"PHASE1","title":"Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-03","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma","enrollment":32},{"nctId":"NCT04751370","phase":"PHASE2","title":"Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-08","conditions":"Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8","enrollment":31},{"nctId":"NCT03604991","phase":"PHASE2, PHASE3","title":"Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-03","conditions":"Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8","enrollment":278},{"nctId":"NCT03952585","phase":"PHASE2, PHASE3","title":"De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-09","conditions":"Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":384},{"nctId":"NCT03866382","phase":"PHASE2","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-13","conditions":"Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma","enrollment":314},{"nctId":"NCT02339571","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-23","conditions":"Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7","enrollment":600},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT03604978","phase":"PHASE1, PHASE2","title":"Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-17","conditions":"Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma","enrollment":38},{"nctId":"NCT05111574","phase":"PHASE2","title":"Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-11","conditions":"Anal Melanoma, Bladder Melanoma, Cervical Melanoma","enrollment":101},{"nctId":"NCT02275533","phase":"PHASE2","title":"Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-07-02","conditions":"Acute Myeloid Leukemia","enrollment":82},{"nctId":"NCT04652960","phase":"PHASE1","title":"Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-21","conditions":"Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8","enrollment":38},{"nctId":"NCT06325683","phase":"PHASE2","title":"Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-11-08","conditions":"Progressive Glioblastoma, Recurrent Glioblastoma","enrollment":184},{"nctId":"NCT04929041","phase":"PHASE2, PHASE3","title":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-07","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma","enrollment":427},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome","enrollment":127},{"nctId":"NCT02453620","phase":"PHASE1","title":"Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-02-12","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma","enrollment":57},{"nctId":"NCT03914300","phase":"PHASE2","title":"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-02-10","conditions":"Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma","enrollment":11},{"nctId":"NCT04310007","phase":"PHASE2","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-13","conditions":"Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":117},{"nctId":"NCT04079712","phase":"PHASE2","title":"Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-06","conditions":"Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Metastatic Neuroendocrine Neoplasm","enrollment":17},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT04609046","phase":"PHASE1","title":"Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-24","conditions":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","enrollment":47},{"nctId":"NCT03899155","phase":"PHASE2","title":"Pan Tumor Rollover Study","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-09","conditions":"Cancer","enrollment":1500},{"nctId":"NCT03391869","phase":"PHASE3","title":"Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-29","conditions":"Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":339},{"nctId":"NCT05987241","phase":"PHASE2, PHASE3","title":"Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-02","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma","enrollment":992},{"nctId":"NCT04514484","phase":"PHASE1","title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-22","conditions":"Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma","enrollment":8},{"nctId":"NCT04462406","phase":"PHASE2","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-09","conditions":"Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":150},{"nctId":"NCT04387084","phase":"PHASE1","title":"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2020-08-12","conditions":"Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm","enrollment":10},{"nctId":"NCT04904302","phase":"PHASE2","title":"Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-05-03","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8","enrollment":15},{"nctId":"NCT05347212","phase":"PHASE2","title":"Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-09-22","conditions":"Carcinomas, Renal Medullary Carcinoma","enrollment":30},{"nctId":"NCT04902040","phase":"PHASE1, PHASE2","title":"Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-04-14","conditions":"Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm","enrollment":19},{"nctId":"NCT03799445","phase":"PHASE2","title":"Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-07-25","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT06618287","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-02-04","conditions":"Lung Cancer, Breast Cancer","enrollment":416},{"nctId":"NCT05098210","phase":"PHASE1","title":"Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-06-09","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma","enrollment":25},{"nctId":"NCT06053658","phase":"PHASE2","title":"Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-05","conditions":"Renal Cell Carcinoma","enrollment":48},{"nctId":"NCT04697576","phase":"PHASE1","title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","status":"RECRUITING","sponsor":"Carlo Contreras","startDate":"2021-10-20","conditions":"Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8","enrollment":36},{"nctId":"NCT04420975","phase":"PHASE1","title":"Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-10-14","conditions":"Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Myxofibrosarcoma","enrollment":14},{"nctId":"NCT04940299","phase":"PHASE2","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-23","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma","enrollment":35},{"nctId":"NCT03036098","phase":"PHASE3","title":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-24","conditions":"Urothelial Cancer","enrollment":1314},{"nctId":"NCT04380545","phase":"PHASE1, PHASE2","title":"Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-13","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8","enrollment":15},{"nctId":"NCT04013542","phase":"PHASE1","title":"Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-09-13","conditions":"ALK Gene Rearrangement, EGFR Gene Mutation, Locally Advanced Lung Non-Small Cell Carcinoma","enrollment":21},{"nctId":"NCT04396860","phase":"PHASE2, PHASE3","title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-01","conditions":"Gliosarcoma, MGMT-Unmethylated Glioblastoma","enrollment":159},{"nctId":"NCT05122546","phase":"PHASE1","title":"CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-11-01","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma, Advanced Renal Cell Carcinoma","enrollment":31},{"nctId":"NCT06745076","phase":"PHASE2","title":"Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-03-06","conditions":"Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8","enrollment":125},{"nctId":"NCT02530463","phase":"PHASE2","title":"Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-08","conditions":"Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome","enrollment":99},{"nctId":"NCT03307616","phase":"PHASE2","title":"Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-04","conditions":"Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma","enrollment":32},{"nctId":"NCT06284564","phase":"PHASE2","title":"A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-08-07","conditions":"Metastatic Renal Cell Carcinoma","enrollment":10},{"nctId":"NCT05647265","phase":"PHASE2","title":"Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-11-27","conditions":"Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma","enrollment":26},{"nctId":"NCT04785287","phase":"PHASE1, PHASE2","title":"Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-29","conditions":"Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm, Malignant Adrenal Gland Neoplasm","enrollment":13},{"nctId":"NCT06561087","phase":"PHASE2","title":"Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-27","conditions":"Premalignant Lesion","enrollment":45},{"nctId":"NCT03358719","phase":"PHASE1","title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2018-03-27","conditions":"Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia","enrollment":8},{"nctId":"NCT07128680","phase":"PHASE1","title":"Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-01","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma","enrollment":33},{"nctId":"NCT05255601","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-09-13","conditions":"Lymphoma, Non-Hodgkin, Hodgkin Disease","enrollment":5},{"nctId":"NCT04895709","phase":"PHASE1, PHASE2","title":"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-05-27","conditions":"Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer","enrollment":949},{"nctId":"NCT03400332","phase":"PHASE1, PHASE2","title":"A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-02-12","conditions":"Cancer, Melanoma","enrollment":281},{"nctId":"NCT03366766","phase":"PHASE2","title":"Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2017-12-20","conditions":"Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Carcinoma","enrollment":14},{"nctId":"NCT04745949","phase":"PHASE2","title":"PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-10","conditions":"Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma","enrollment":31},{"nctId":"NCT02224781","phase":"PHASE3","title":"Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-08","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma","enrollment":267},{"nctId":"NCT04339738","phase":"PHASE2","title":"Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-11-04","conditions":"Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma","enrollment":89},{"nctId":"NCT02940301","phase":"PHASE2","title":"Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2016-12-20","conditions":"Classical Hodgkin Lymphoma","enrollment":18},{"nctId":"NCT03600155","phase":"PHASE1","title":"Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-10-11","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":29},{"nctId":"NCT03143153","phase":"PHASE3","title":"A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-06-29","conditions":"Various Advanced Cancer","enrollment":970},{"nctId":"NCT03785873","phase":"PHASE1, PHASE2","title":"Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2019-05-22","conditions":"Biliary Tract Cancer","enrollment":34},{"nctId":"NCT06731270","phase":"PHASE2","title":"Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-04-09","conditions":"Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":20},{"nctId":"NCT03749018","phase":"PHASE2","title":"Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Bond, MD","startDate":"2019-01-02","conditions":"Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT05234307","phase":"PHASE1","title":"PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Dwight Owen","startDate":"2022-11-21","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":30},{"nctId":"NCT03465592","phase":"PHASE1, PHASE2","title":"Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-05-01","conditions":"Sarcoma, Solid Tumor, Adult, Solid Tumor, Childhood","enrollment":39},{"nctId":"NCT07383441","phase":"PHASE3","title":"Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-06-10","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8","enrollment":718},{"nctId":"NCT03661320","phase":"PHASE3","title":"A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2018-11-06","conditions":"Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer","enrollment":855},{"nctId":"NCT04362839","phase":"PHASE1","title":"Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-05-27","conditions":"Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma","enrollment":39},{"nctId":"NCT03338790","phase":"PHASE2","title":"An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-12-19","conditions":"Prostate Cancer","enrollment":292},{"nctId":"NCT02648997","phase":"PHASE2","title":"An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-03","conditions":"Meningiomas","enrollment":40},{"nctId":"NCT05136677","phase":"PHASE2","title":"A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-01-25","conditions":"Mesothelioma, Malignant","enrollment":102},{"nctId":"NCT04599140","phase":"PHASE1, PHASE2","title":"SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-10-14","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma","enrollment":51},{"nctId":"NCT03829722","phase":"PHASE2","title":"Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2019-09-05","conditions":"Oropharynx Squamous Cell Carcinoma","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12503,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BMS-936558 (Nivolumab)","genericName":"BMS-936558 (Nivolumab)","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Biologic","firstApprovalDate":"","aiSummary":"Nivolumab blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells. Used for Metastatic melanoma, Advanced non-small cell lung cancer, Renal cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}